Abstract
Purpose
Peptides with restricted conformation provide increased affinity and stability against degradation as compared to linear peptides. This study investigates the characteristics of derivatives of the sunflower trypsin inhibitor 1 (SFTI-1), a 14 amino acid peptide with high intrinsic stability.
Methods
Three SFTI-1 derivatives (cyclic cSFTI, acyclic oSFTI, and DOTA-SFTI) were generated by Fmoc-based automated synthesis. Thereafter, the inhibitory activity for trypsin was determined. After radiolabeling, kinetic and competition studies were done in a variety of tumor cell lines including prostate carcinoma, colon carcinoma, mammary carcinoma, and hepatoma to characterize the binding affinity of the peptides. The stability was determined by incubating the molecules in human serum for increasing time periods. Furthermore, the biodistribution was measured in nude mice bearing human prostate carcinomas.
Results
The inhibitory constants for trypsin inhibition were 0.08 nM (cSFTI), 0.15 nM (oSFTI), and 0.3 nM (DOTA-SFTI). Among the different tumor cell lines evaluated, the prostate cancer cell lines PC-3 and DU-145 showed the highest accumulation of the radiolabeled peptides. The open-chain derivatives generally bound better than the cyclic one. Binding was constant during 4 h and could be competed by addition of the cold peptide up to 75%. The stability in serum revealed half-lives of 75.8 h for cSFTI, 34.5 h for oSFTI, and 41.7 h for DOTA-SFTI. The biodistribution showed a rapid renal clearance for all three compounds and tumor uptake values up to 3%ID/g.
Conclusions
SFTI derivatives are small stable molecules readily accessible by solid-phase synthesis. The trypsin inhibition was not influenced by the cyclization, and addition of a chelator had no significant influence. The exceptional rigidity and stability allow the use of SFTI derivatives as scaffolds for the introduction of tumor-specific peptide motifs which could be used to increase cell-binding affinities and thus their use as diagnostic and/or therapeutic tools.
Similar content being viewed by others
References
Wängler C, Wängler B, Eisenhut M, Haberkorn U, Mier W (2008) Improved syntheses and applicability of different DOTA building blocks for multiply derivatized scaffolds. Bioorg Med Chem 16:2606–2616
Haberkorn U, Eisenhut M, Altmann A, Mier W (2008) Endoradiotherapy with peptides–status and future development. Curr Med Chem 15:219–234
Haberkorn U, Eisenhut M (2005) Molecular imaging and therapy-a programme based on the development of new biomolecules. Eur J Nucl Med Mol Imaging 32:1354–1359
Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D et al (2005) Trypsin inhibition by macrocyclic and open-chain variants of the squash inhibitor MCoTI-II. Biol Chem 386:1301–1306
Chase T Jr, Shaw E (1967) p-Nitrophenyl-p′-guanidinobenzoate HCl: a new active site titrant for trypsin. Biochem Biophys Res Commun 29:508–514
Bieth JG (1995) Theoretical and practical aspects of proteinase inhibition kinetics. Methods Enzymol 248:59–84
Morrison JF (1969) Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 185:269–286
Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Krämer S, Altmann A, Eisenhut M, Haberkorn U (2005) A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res 11:139–146
Zitzmann S, Krämer S, Mier W, Mahmut M, Fleig J, Altmann A, Eisenhut M, Haberkorn U (2005) Identification of a New Prostate-Specific Cyclic Peptide with the Bacterial FLiTRx System. J Nucl Med 46:782–785
Askoxylakis V, Zitzmann S, Mier W, Graham K, Krämer S, von Wegner F, Fink RHA, Schwab M, Eisenhut M, Haberkorn U (2005) Preclinical evaluation of the breast cancer cell binding peptide p160. Clin Cancer Res 11:6705–6712
Nothelfer EM, Zitzmann-Kolbe S, Garcia-Boy R, Krämer S, Herold-Mende C, Altmann A, Eisenhut M, Mier W, Haberkorn U (2009) Identification and characterization of a peptide with affinity to head and neck cancer. J Nucl Med 50:426–434
Jaulent AM, Leatherbarrow RJ (2004) Design, synthesis and analysis of novel bicyclic and bifunctional protease inhibitors. Protein Eng Des Sel 17:681–687
Korsinczky ML, Schirra HJ, Rosengren KJ et al (2001) Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sunflower seeds and an acyclic permutant. J Mol Biol 311:579–591
Hilpert K, Hansen G, Wessner H, Volkmer-Engert R, Hohne W (2005) Complete substitutional analysis of a sunflower trypsin inhibitor with different serine proteases. J Biochem 138:383–390
Daly NL, Chen YK, Foley FM et al (2006) The absolute structural requirement for a proline in the P3′-position of Bowman-Birk protease inhibitors is surmounted in the minimized SFTI-1 scaffold. J Biol Chem 281:23668–23675
Jaulent AM, Brauer AB, Matthews SJ, Leatherbarrow RJ (2005) Solution structure of a novel C2-symmetrical bifunctional bicyclic inhibitor based on SFTI-1. J Biomol NMR 33:57–62
Korsinczky ML, Schirra HJ, Craik DJ (2004) Sunflower trypsin inhibitor-1. Curr Protein Pept Sci 5:351–364
Zablotna E, Kret A, Jaskiewicz A, Olma A, Leplawy MT, Rolka K (2006) Introduction of alpha-hydroxymethyamino acid residues in substrate specificity P1 position of trypsin inhibitor SFTI-1 from sunflower seeds retains its activity. Biochem Biophys Res Commun 340:823–828
Descours A, Moehle K, Renard A, Robinson JA (2002) A new family of beta-hairpin mimetics based on a trypsin inhibitor from sunflower seeds. Chembiochem 3:318–323
Brauer AB, Kelly G, Matthews SJ, Leatherbarrow RJ (2002) The (1)H-NMR solution structure of the antitryptic core peptide of Bowman-Birk inhibitor proteins: a minimal canonical loop. J Biomol Struct Dyn 20:59–70
Acknowledgments
The authors want to acknowledge the contribution of U. Hebling to the in vitro experiments and U. Schierbaum and K. Leotta to the animal experiments. This work has been supported by the DFG grants HA2901/5-1, 5-2 and 6-1.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
García Boy, R., Mier, W., Nothelfer, E.M. et al. Sunflower Trypsin Inhibitor 1 Derivatives as Molecular Scaffolds for the Development of Novel Peptidic Radiopharmaceuticals. Mol Imaging Biol 12, 377–385 (2010). https://doi.org/10.1007/s11307-009-0287-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-009-0287-z